Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Earnings momentum for the S&P

Fri, 12th Mar 2021 10:22

March 12 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

EARNINGS MOMENTUM FOR THE S&P (1015 GMT)

The U.S. are expected to offset the adverse impact of rising
yields with a strong recovery coupled with expansion of
earnings, which is the main equity key driver.

“Much better than expected earnings should drive further S&P
500 upside through 2021,” UBS analysts say.

"We raise our S&P 500 price target for year end to 4250,
from 4100, on higher forecasted EPS of $188 for 2021 and $218
for 2022", they add.

While the Fed's policy will be crucial as higher rates have
an impact on stock valuations, politics also have to be closely
monitored. More corporate and capital gains taxes coupled with
greater regulation would reduce UBS estimates by 12%.

(Stefano Rebaudo)

*****

EUROPE ON THE BACKFOOT (0837 GMT)

A cocktail of reasons for the pullback in Europe this
morning, despite strong sessions in U.S. and Asia overnight. The
Stoxx 600 index is however comfortably poised to record a gain
for the week.

Concerns about the vaccination campaign, with AstraZeneca
further cutting its supply forecast are dampening risk
sentiment.

Then we have yields on the rise above 1.6% in early London
trading and China warning the United States to stop interfering
in its affairs, including Hong Kong.

The Stoxx 600 index is down 0.3%, with Tech stocks leading
losses down 1.2%, inline with Nasdaq futures.

Shares in online investor Prosus are down 4.4%,
after China's watchdog imposed administrative penalties on 12
companies including Internet giants Tencent and Baidu for
violating anti-monopoly law in 10 deals.

Bank stocks are in positive territory after
yesterday’s strong post-ECB selloff.

Burberry is the best performer of Stoxx 600, up 7%,
after the company raised its outlook.

(Stefano Rebaudo)

*****

TROUBLE RETURNS (0811 GMT)

U.S. 10-year Treasury yields are on track to rise for the
seventh week straight. But a measure of calm that had returned
in recent days seems to have dissipated on Friday as yields are
making their way back towards recent one-year highs above 1.6%.

Euro zone yields too are higher this morning, though to a
lesser extent, still benefiting from the ECB's promise to
accelerate emergency money-printing.

That in turn is putting the dampener on stock markets --
world stocks rose three days in a row as U.S. yields pulled back
but are now turning tail -- Nasdaq futures are down 1%. Futures
for the S&P500 and for European stocks are also weaker, albeit
to a lesser degree.

So what's going on? Jobs data on Thursday indicated the U.S.
economy is well on the road to recovery while President Joe
Biden signed into law a $1.9 trillion COVID-19 relief bill and
a 30-year Treasury auction had a mixed outcome.

That was partly down to dealers offloading Treasuries to
hedge a corporate bond deal from Verizon, it nonetheless
continues to suggest persistent uncertainty about appetite for
U.S. government debt.

And as the risk sentiment sours going into the weekend, the
dollar has risen off one-week low against its rivals, slamming
currencies such as the euro and Aussie dollar almost half a
percent lower. An index of emerging market currencies which on
Thursday posted its biggest rise since early-January has fallen
back.

But it's not all bad news. The Nasdaq, despite a recent
recovery, remains well behind the Dow 30, S&P and Russell 2000
indexes which have hit records -- clearly investors, seeing
economic recovery on the horizon, are piling into old economy
stocks such as banks and energy.

Key developments that should provide more direction to markets
on Friday:
-Britain's economy shrank by 2.9% in January from December
-Brent oil prices ease but stay near $70 a barrel
-British luxury group Burberry raises outlook after strong
bounceback in sales;
-Apple's market value could breach $3 trillion if the iPhone
maker successfully makes Apple Car, Citi says,
-Euro area industrial production
-Canada employment report

(Saikat Chatterjee)

*****

EUROPEAN FUTURES TAKE A BREATHER (0633 GMT)

European stock futures are pointing to a session flat or
slightly in the red, as equities seem keen on taking a breather
after a rally which drove the Stoxx 600 index close to
pre-pandemic levels.

Germany’s Dax has been hitting fresh record highs since the
start of the week and many Europe’s benchmark sectoral indexes
are at their highest levels or close to them.

The bigger picture remains favourable to risk sentiment
after the ECB announced an increase of PEPP buying pace to keep
a lid on borrowing costs, while subsiding inflation fears
boosted Wall Street and Asian stocks overnight.

(Stefano Rebaudo)

*****

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.